AGENUS INC Payments for Repurchase of Equity
Shares the company repurchased and the cash it paid, as filed in its 10-Q and 10-K XBRL (statement of shareholders' equity and cash flow statement).
- AGENUS INC payments for repurchase of equity for the quarter ending 2023-12-31 was $42.00K.
- AGENUS INC payments for repurchase of equity for the quarter ending 2023-09-30 was $328.00K.
- AGENUS INC payments for repurchase of equity for fiscal 2023 was $606.00K.
| Period end | Payments for Repurchase of Equity 3 month | Payments for Repurchase of Equity 12 month |
|---|---|---|
| 2023-12-31 | $42.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | $606.00K 10-K · filed 2024-03-14 |
| 2023-09-30 | $328.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |